Hyperfine, Inc. (HYPR) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings report shows strong financial performance with significant revenue and gross profit growth, reduced net loss, and improved cash burn. The optimistic guidance for 2026, strong pipeline, and increased pricing for Model 2 suggest positive future prospects. Despite some management avoidance in addressing specific deal sizes, the overall sentiment is positive, supported by the transition to broader clinical utility and strategic market expansion.
Key Financial Performance
Revenue for Q4 2025 $5.3 million, up 128% year-over-year compared to $2.3 million in Q4 2024. The increase was driven by demand across hospitals, neurology offices, and international markets, as well as multiple unit placements and technology upgrades.
Revenue for full year 2025 $13.6 million, up 5% year-over-year compared to $12.9 million in 2024. Growth was attributed to significant revenue generation in the second half of the year due to midyear product launches.
Gross profit for Q4 2025 $2.7 million, up 226% year-over-year compared to Q4 2024. Gross margin was 50.9%, representing a 1,530 basis point expansion over Q4 2024. This was due to healthy margins and scaling of operations.
Gross profit for full year 2025 $6.8 million, up 15% year-over-year compared to 2024. Full-year gross margin was 49.8%, representing a 410 basis point expansion over 2024, driven by scaling and operational efficiencies.
R&D expenses for Q4 2025 $3.8 million, down 25% year-over-year compared to $5.1 million in Q4 2024. The decline was due to benefits realized from a reorganization completed in Q1 2025.
R&D expenses for full year 2025 $17.5 million, down 22% year-over-year compared to $22.5 million in 2024. The reduction was attributed to the transition to a commercial growth stage organization.
Sales, general, and administrative expenses for Q4 2025 $6.5 million, flat year-over-year compared to Q4 2024. Spending discipline and sales productivity were maintained.
Sales, general, and administrative expenses for full year 2025 $26.4 million, slightly down compared to $26.6 million in 2024. Spending discipline and operating leverage contributed to the stability.
Net loss for Q4 2025 $5.9 million, compared to a net loss of $10.4 million in Q4 2024. The improvement was due to increased revenue and reduced expenses.
Net loss for full year 2025 $35.6 million, compared to a net loss of $40.7 million in 2024. The improvement was driven by higher revenue and cost management.
Net cash burn for Q4 2025 $5.7 million, down 30% year-over-year compared to $8.2 million in Q4 2024. The reduction was due to spending discipline and operational efficiencies.
Net cash burn for full year 2025 $29.9 million, down 22% year-over-year compared to $38.4 million in 2024. The decline was attributed to spending discipline and reduced expenses.
Cash and cash equivalents as of December 31, 2025 $35.1 million, inclusive of $18.4 million in net proceeds from October equity financing but not including $15 million from a new long-term debt facility.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Next-generation Swoop system: The next-generation Swoop system with Optive AI software was introduced mid-2025, marking a turning point in portable brain MRI adoption. It offers diagnostic quality images with an ultra-low field magnet and has been validated for clinical and economic value. FDA clearance was received for updates to the Optive AI software, enhancing stroke detection capabilities.
Clinical advancements: The Swoop system demonstrated 92%-98% concordance with standard MRI in identifying intracranial pathology. It has been validated for stroke triage and patient care in neurology offices, with significant patient preference for portable MRI over standard MRI.
Neurology office market: Neurology offices represent a significant growth opportunity, with only 10% of private practices having on-site MRI imaging. The company has accelerated selling efforts and implemented a segmentation pricing strategy to cater to practices of varying sizes.
International expansion: Regulatory approval was received in India, and the Optive AI software was launched in 10 European languages. Plans are underway to bring the next-generation Swoop scanner to the U.K. and CE markets by the end of 2026.
Revenue growth: Q4 2025 revenue was $5.3 million, up 128% YoY. Full-year 2025 revenue reached $13.6 million, with significant growth in the second half due to product launches.
Cost management: Net cash burn for 2025 was reduced by 22% YoY to $29.9 million. Gross margin expanded to 50.9% in Q4 2025, demonstrating scalability and operational efficiency.
Strategic partnerships and studies: Collaborations with Yale and other institutions are validating the Swoop system's utility in emergency departments and neurology offices. The PRIME study and contrast PMR study aim to expand use cases and FDA approvals.
Long-term growth strategy: The company raised $20 million in equity and $15 million in debt to extend its cash runway into 2028. It plans to release 1-2 software updates annually and expand into new markets and use cases.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Activation Variability: Larger deals with hospitals and IDNs have increased administrative processes and are now more dependent on budget cycles, creating potential for quarterly lumpiness and variability in revenue.
Regulatory and Geographic Expansion Challenges: The company is navigating the European regulatory process to bring the next-generation Swoop scanner to the U.K. and CE markets, which could delay international market expansion. Additionally, scaling placements in India is expected to progress at a measured pace, indicating potential delays in capturing market share.
Economic and Operational Risks: The company is reliant on achieving a 1- to 1.5-year return on investment for hospitals, which, while better than typical capital equipment, still depends on hospitals' financial health and decision-making processes. Additionally, the company has a significant cash burn, with a projected $26 million to $28 million cash burn for 2026, which could strain resources if revenue growth does not meet expectations.
Competitive and Market Risks: The neurology office market, while a significant growth vector, has minimal incumbent competition, but the company must prove its value proposition to penetrate this market effectively. Additionally, the company is dependent on the adoption of its technology in new settings like neurosurgical and neurointerventional settings, which may take time to materialize.
Product Development and Adoption Risks: The company is heavily reliant on continuous innovation and clinical data generation to support its growth. Delays in FDA submissions, such as the late 2026 submission for expanded use of the Swoop system, could impact the timeline for new product applications and market adoption.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Outlook for 2026: Hyperfine expects revenue between $20 million to $22 million for the full year 2026, representing year-over-year growth at the midpoint of 55%. Revenue is expected to progressively strengthen through the quarters in 2026.
Gross Margin Guidance for 2026: Gross margin is expected to range between 50% to 55% for the year, with second-half gross margin percentages exceeding the first half.
Cash Burn Expectations for 2026: Total cash burn is expected to range between $26 million to $28 million for the full year 2026, representing a 10% year-over-year decline in cash burn at the midpoint. This includes debt servicing.
Product Development and FDA Submission: Hyperfine plans to release 1 to 2 software updates per year for the Optive AI software. A prospective multicenter clinical study is underway to evaluate contrast-enhanced ultra-low field portable MRI, with a future FDA submission planned for late 2026 to expand the Swoop system's intended use.
International Expansion: The company plans to launch the next-generation Swoop scanner in international markets, including the U.K. and CE markets, in the second half of 2026. Regulatory approval in India has been obtained, with placements expected to scale throughout the year.
Market Expansion and Use Cases: Hyperfine is actively expanding into neurology offices, neurosurgical and neurointerventional settings, and mobile units for dementia screening research. The company is also targeting broader adoption in emergency departments for faster stroke triage.
Pipeline and Strategic Deals: The hospital pipeline is experiencing increased activity, with larger, more strategic deals involving multiple placements. These deals are expected to progress over multiple quarters.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the key assumptions surrounding the 2026 guidance?
A:The 2026 guidance is based on three business verticals: hospital business (multiunit systems and IDNs), office business (traction in NEURO-PMR data and penetration), and international business (second-generation scanner expected in the second half of the year). Pricing has increased for Model 2 to $590,000 from $550,000, with price segmentation for Model 1 and Model 2 in office settings. The U.S. hospital business predominantly uses Model 2, benefiting from the price increase. ROI calculations show a 1-1.5 year return even at $590,000.
Q:Does the pipeline remain strong and diversified?
A:Yes, the pipeline is the strongest and most diversified it has ever been, with multiple deals and IDN deals in progress. These deals are more mainstream procurement and dependent on budget years, with larger deals expected to strengthen revenue progressively throughout the year.
Q:Are there potential double-digit multi-unit deals in the pipeline?
A:Multi-unit deals are typically single-digit in individual transactions. For individual hospitals, there may be multiple placement opportunities (e.g., critical care, emergency department, pediatric, and adult). For IDNs, deals may start with one hospital and expand across the network over time.
Q:What lessons have been learned from the business's ups and downs over the past few years?
A:The introduction of Model 2 and Optive AI software has significantly improved image quality, making the technology more clinically useful and comparable to high-field MRI. This has led to increased endorsement and interest, with the technology now being used for triage in suspected stroke cases and other clinical decisions. The business is transitioning from a development phase to broader clinical utility.
Q:Why was service revenue lower in Q4 despite more devices being installed?
A:Service revenue was impacted by accounting adjustments related to technology upgrades and contract assessments. However, the long-term trajectory of service revenue is expected to grow as more devices are installed.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing whether there are potential double-digit multi-unit deals in the pipeline, providing only general information about single-digit transactions and the process for IDN deals.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI software
Brett
ED
FDA
Optive AI
PMR
RD decline
Swoop scanner
Swoop software
Swoop system
brain health
burn expectation
capital cash
capital financing
commitment
concordance
contrast
debt facility
department neurology
diffusion imaging
equity
expansion opportunity
feedback Swoop
generation Swoop
hospital neurology
period loss
perspective
placement hospital
point care
point margin
position
potential
productivity leverage
publication
sale productivity
software release
staff
supply
system Optive
term debt
tranche
HYPR Transcript
Hyperfine, Inc. (HYPR) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Neutral6-5
Hyperfine, Inc. (HYPR) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call indicated strong financial performance with an 83% revenue increase and improved gross margins. The strategic plan outlines international expansion and product development, while the Q&A section highlighted positive reception of the Swoop system and no impact from helium shortages. Despite a net loss, reduced R&D expenses and cash burn demonstrate financial discipline. The guidance aligns with growth initiatives, and the company's innovative approach and market potential suggest a positive stock price movement in the near term.
AutoCanada Inc. (ACQ:CA) Q4 2025 Earnings Call Transcript
Unknown3-18
The earnings call revealed significant challenges, including declining revenue and gross profit, operational disruptions, and inventory management issues. The Q&A highlighted ongoing pressures on used vehicle gross profit and the need for a strategic reset. Although there is potential for improvement in the long term, the immediate outlook remains negative due to these persistent challenges and market underperformance.
Hyperfine, Inc. (HYPR) Q4 2025 Earnings Call Transcript
Positive3-18
The earnings report shows strong financial performance with significant revenue and gross profit growth, reduced net loss, and improved cash burn. The optimistic guidance for 2026, strong pipeline, and increased pricing for Model 2 suggest positive future prospects. Despite some management avoidance in addressing specific deal sizes, the overall sentiment is positive, supported by the transition to broader clinical utility and strategic market expansion.
HYPR Slides
HYPR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
